MagVenture MagPro System with Brainsight neuronavigation device for Depression
This trial will test a new accelerated 5-day rTMS protocol for treating symptoms of depression and OCD. The goal is to improve symptoms and identify biomarkers for depression and OCD.
- Obsessive-Compulsive Disorder
2 Primary · 10 Secondary · Reporting Duration: Baseline to Treatment End: Day 5, 10, 15, or 20 (depending on number of 5-day treatment courses administered)
4 Treatment Groups
OCD - LPFC target to (for non-responders) DMPFC target
1 of 4
Depression - LPFC target to (for non-responders) DMPFC target
1 of 4
Depression - DMPFC target to (for non-responders) LPFC target
1 of 4
OCD - DMPFC target to (for non-responders) LPFC target
1 of 4
300 Total Participants · 4 Treatment Groups
Primary Treatment: MagVenture MagPro System with Brainsight neuronavigation device · No Placebo Group · N/A
Who is running the clinical trial?
Age 18 - 70 · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|Weill Cornell Medicine||100.0%|
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Frequently Asked Questions
What is the sample size of this research study?
"Yes, according to clinicaltrials.gov this medical research is presently recruiting patients. Initially posted on August 18th 2021 and last edited June 27th 2022, the study seeks 300 participants at a single site." - Anonymous Online Contributor
What are the eligibility requirements for participation in this research project?
"This clinical trial, which is open to adults aged 18-70 with depression and OCD, seeks 300 participants. The necessary criteria for enrolment include a failure of current treatment despite adequate dosing; DSM-V diagnosis of major depressions disorder or obsessive compulsive disorder; Hamilton Depression Rating Scale score greater than 18 OR Yale-Brown Obsessive Compulsive Scale score higher than 16; stable dose of antidepressants for at least 4 weeks with plans to remain on this dosage during the study; and capacity to give informed consent." - Anonymous Online Contributor
Does this trial accept senior citizens as participants?
"This medical trial is open to patients who are 18 years or older, but not yet 70." - Anonymous Online Contributor
Are there still opportunities available to participate in this medical experiment?
"Per the clinicaltrials.gov registry, this research is actively recruiting patient populations; the study was first advertised on August 18th 2021 and underwent its latest update June 27th 2022." - Anonymous Online Contributor
What are the key objectives of this experimental procedure?
"Over the Baseline to Treatment End: Day 5, 10, 15 or 20 (depending on number of courses administered) period for this trial, investigators will assess the Percent Change in Yale-Brown Obsessive Compulsive Scale scores. Additionally, they shall measure the change in Beck Anxiety Inventory results (ranging from 0 - 63), General Anxiety Disorder rankings (from 0 - 21), and resting-state fMRI connectivity between frontostriatal network and limbic network (between 0 - 1)." - Anonymous Online Contributor